Welcome to our dedicated page for Capricor Therapeutics SEC filings (Ticker: CAPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Capricor Therapeutics filings document a Delaware biotechnology issuer developing cell and exosome-based therapeutics, including Deramiocel for Duchenne muscular dystrophy. Its 8-K reports record quarterly and annual financial results, FDA communications tied to the Deramiocel Biologics License Application, Regulation FD disclosures, and material-event reporting for litigation-related actions.
Proxy materials address board elections, executive compensation, equity awards, shareholder voting matters, and other governance disclosures. The filing record also identifies CAPR common stock, par value $0.001 per share, as a Nasdaq-listed security and provides formal disclosure around operating results, capital structure, and public-company status.
Capricor Therapeutics, Inc. reported that its Chief Executive Officer and director, Linda Marban, received new equity awards on January 5, 2026. She was granted stock options to buy 50,000 shares at $24.81 per share that vest in equal monthly installments of 1/48 beginning February 1, 2026, with an early exercise feature that allows purchase before vesting subject to a company repurchase right. She also received stock options for 100,000 shares at $24.81 per share that vest and become exercisable only upon U.S. Food and Drug Administration approval of Deramiocel, contingent on her continued service. In addition, she was granted 7,500 restricted stock units under the 2025 Equity Incentive Plan, vesting 25% annually starting February 1, 2027, also conditioned on continued service.
Capricor Therapeutics reported that its Chief Financial Officer, Anthony Bergmann, received new equity awards on January 5, 2026. He was granted two stock options, each covering 25,000 shares of common stock at an exercise price of $24.81 per share, and 2,500 restricted stock units (RSUs).
One 25,000-share option vests in equal monthly installments of 1/48th beginning on February 1, 2026, and is subject to an early exercise feature, with unvested shares subject to repurchase if his service ends. The second 25,000-share option vests and becomes exercisable on the date of U.S. Food and Drug Administration approval of Deramiocel, conditioned on his continued service.
Each RSU represents one share of common stock under the company’s 2025 Equity Incentive Plan. The 2,500 RSUs were granted as part of the annual equity grant to executive officers and vest 25% annually starting on February 1, 2027, subject to continued service.
Capricor Therapeutics executive Karen Krasney, EVP and General Counsel, reported two new stock option awards. Each award is a stock option to buy 22,500 shares of Capricor common stock at an exercise price of $24.81 per share, with no purchase price for receiving the options themselves. One option grant vests in equal monthly installments of 1/48 of the shares on the first day of each month starting February 1, 2026, until fully vested, and includes an early exercise feature with a company repurchase right if service ends before vesting. The second option grant vests and becomes exercisable only on the date the U.S. Food and Drug Administration approves Deramiocel, subject to Krasney’s continued service with the company through that approval date.
Capricor Therapeutics director Paul Gisbert Auwaerter reported stock option grants for board and committee service. On January 5, 2026, he received three awards of stock options, each with an exercise price of $24.81 per share. The grants cover 15,500 shares that vest in 12 monthly installments beginning February 1, 2026, plus two fully vested grants for 1,360 shares and 5,420 shares that were exercisable immediately on January 5, 2026. The partially vesting award includes an early exercise feature, allowing purchase before vesting, with unvested shares subject to a company repurchase right if his service ends.
Capricor Therapeutics director Mike Kelliher reported receiving a stock option grant related to annual board service. On January 5, 2026, he was awarded an option to buy 15,500 shares of common stock at an exercise price of $24.81 per share, all held directly.
The option vests in equal monthly installments, with 1/12 of the grant vesting on the first day of each month starting February 1, 2026, and the final portion vesting on December 31, 2026, after which it is fully vested and exercisable. The option is subject to early exercise, meaning some or all shares can be purchased before they vest, but any such early-exercised shares will be treated as restricted stock and may be repurchased by the company if Kelliher’s service ends before vesting.
Capricor Therapeutics director Philip J. Gotwals received a stock option grant for 15,500 shares on January 5, 2026. The option has a conversion or exercise price of $24.81 per share and was acquired at a price of $0 as compensation.
The award relates to annual board service and vests in monthly installments. One-twelfth of the option vests on the first day of each month starting February 1, 2026, with the final vesting on December 31, 2026, when it becomes fully exercisable. The option is subject to early exercise, meaning all or part of it can be exercised before vesting, but any such early-exercised shares are treated as restricted stock and may be repurchased by the company if Gotwals’ service ends before they vest.
Capricor Therapeutics director Sabar Karimah Es received a new stock option grant related to annual board service. The grant covers 15,500 stock options with an exercise price of $24.81 per share. The options vest in 12 equal monthly installments, with 1/12 of the award vesting on the first day of each month from February 1, 2026 through December 31, 2026, making the option fully vested by year-end 2026.
The option is subject to early exercise, meaning all or part of it can be exercised before vesting. Any shares purchased early are treated as restricted stock and may be repurchased by the company if the director’s service ends before the relevant vesting dates. After this grant, the director beneficially owns 15,500 derivative securities directly.
Capricor Therapeutics director David B. Musket received a new stock option award for 15,500 shares of common stock. The option has an exercise price of $24.81 per share and was granted on January 5, 2026 for his annual board service.
The option vests in equal 1/12 installments on the first day of each month from February 1, 2026 through December 31, 2026, when it becomes fully vested and exercisable. It is also subject to an early exercise feature, allowing Musket to purchase shares before they vest, but any such early‑exercised shares are treated as restricted stock and can be repurchased by the company if his service ends before vesting is complete.
Capricor Therapeutics director George W. Dunbar Jr. reported receiving a new stock option grant. On 01/05/2026, he was awarded a stock option to buy 15,500 shares of common stock at an exercise price of $24.81 per share. The Form 4 shows this as an acquisition of derivative securities held directly, with 15,500 derivative securities beneficially owned after the transaction.
The option vests in equal monthly installments, with 1/12 of the grant vesting on the first day of each month from February 1, 2026 through December 31, 2026, when it becomes fully vested and exercisable. The award relates to annual board service and is subject to early exercise, meaning all or part of the option may be exercised at any time. If Mr. Dunbar exercises early before vesting, the underlying shares are treated as restricted stock and may be repurchased by the company if his service ends before they vest.
Capricor Therapeutics director Frank Litvack reported a new equity award linked to his board service as Executive Chairman. On January 5, 2026, he received a stock option to buy 50,000 shares of Capricor common stock at an exercise price of $24.81 per share. Following this grant, he beneficially owns 50,000 derivative securities directly.
The option vests over 2026, with 1/12 of the shares vesting on the first day of each month starting February 1, 2026 and the final portion vesting on December 31, 2026, when the award becomes fully vested and exercisable. The option is subject to early exercise, meaning all or part can be exercised at any time; any shares purchased before vesting will be treated as restricted stock and may be repurchased by the company if his service ends before those shares vest.